European pharmaceutical company MGC Pharmaceuticals (ASX:MXC) has announced that its ArtemiC medicinal product has been listed as an over-the-counter, non-prescription drug in the US.
The listing follows the product's admission to the FDA National Drug Code Database via MGC's US supply and distribution partner, AMC Pharma USA.
Following the listing, AMC Pharma has placed a purchase order for ArtemiC to the value of US$2M.
ArtemiC is a clinically tested, all-natural treatment for Covid-19 and has demonstrated benefits for patients suffering from moderate cases of the virus.